Volume 10, Number 3—March 2004
Dispatch
Patient Data, Early SARS Epidemic, Taiwan
Figure 2

Figure 2. Timeline of therapeutic modalities used in 10 patients with severe acute respiratory syndrome (SARS). IVIG, intravenous immunoglobulin (1 g/kg/d for 2 days). IV corticosteroid, intravenous methylprednisolone (500 mg every day for 3 days, followed by 40 mg every 8 h in patient 9 or 40 mg every 8 h in other patients for 4 to 5 days and then tapered for 1 to 2 weeks). The dosage of oral ribavirin was 2,000 mg initially, then 600 mg every 12 h (or 2,000 mg every day) for 10 days and 0.8 mg/kg every day for inhalational use. Fat arrow, date of discharge.
1Pan-Chyr Yang and Chuan-Liang Kao contributed equally to this article.
2The SARS Research Group of National Taiwan University College of Medicine and National Taiwan University Hospital includes the following members: Ding-Shinn Chen, Yuan-Teh Lee, Che-Ming Teng, Pan-Chyr Yang, Hong-Nerng Ho, Pei-Jer Chen, Ming-Fu Chang, Jin-Town Wang, Shan-Chwen Chang, Chuan-Liang Kao, Wei-Kung Wang, Cheng-Hsiang Hsiao, and Po-Ren Hsueh.